Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Shares of pharmaceutical giant Eli Lilly have been falling in recent months. The company updated its guidance last week, and investors weren't impressed. It could be a tough year for Eli Lilly ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Eli Lilly (LLY) shares traded down ... as well as a number of upcoming catalysts." Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA.

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro ... with consumers on a deeper level. Lilly’s position underscores the importance of consistent and pervasive marketing.

After years of preparation, Eli Lilly is on the brink of launching ... The Tempo pen is currently compatible with three of Lilly's insulin products, including Humalog and Lyumjev, both insulin ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...